Improving Keloids Using Targeted Ultraviolet-B Irradiation

Johns Hopkins University

Status: Completed

Conditions: Keloid

Treatments: Device: NB-UVB

Study type: Interventional

Funder types: Other

Identifiers

NCT03160053

IRB00055540

Details and patient eligibility

About

Treatment of keloids with targeted Ultraviolet-Beta (UVB) radiation will improve the clinical appearance and induration of lesions.

Enrollment: 2 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Participants must be 18 years old or over
• Participants must have a diagnosis of keloid
• No treatment with topical or intralesional steroids for 1 month prior to study

Exclusion criteria

• Patients who are unable to provide informed consent
• A history of photosensitivity, lupus erythematosus, porphyria or current use of a known photosensitizing drug
• Unwillingness to stop with topical or intralesional steroids for 1 month prior to study
• A history of malignant melanoma
• A history of radiation therapy to area of interest
• Subjects who self-report that they are pregnant or nursing

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

2 participants in 2 patient groups

Treatment Group

Experimental group

Description:

Keloids that were randomized to the treatment group, were exposed to Narrowband-UVB (NB-UVB). Targeted UVB will be delivered to the keloid for up to 16 weeks using the Lumera UVB light phototherapy device (Daavlin, Bryan Ohio, USA).The affected skin will be irradiated using a hand-held fiber optic cable with an adjustable aperture.

Treatment:

Device: NB-UVB

Control Group

No Intervention group

Description:

Keloids that were randomized to a non treatment group, were not exposed to the NB-UVB light.